Supraglottic Oxygenation Via Oral Transtracheal Catheter for Reducing the Incidence of Hypoxemia During ERCP Under Sedation

Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorZhejiang University

About this trial

Endoscopic retrograde cholangiopancreatography (ERCP) is commonly used for the diagnosis and treatment of pancreatobiliary diseases. While Monitored Anesthesia Care (MAC) enhances the efficiency of ERCP, deep sedation introduces significant airway risks, particularly hypoxemia resulting from sedative-induced upper airway collapse. With reported hypoxemia rates ranging from 10% to 69%, and the potential for severe complications such as myocardial ischemia and neurological damage, effective airway management is paramount. Supraglottic oxygenation via oral transtracheal catheter provides a viable method for relieving obstruction and enabling positive pressure ventilation, serving as a less invasive alternative to tracheal intubation. Despite its proven utility in other settings, this technique has not yet been evaluated in the context of deeply sedated ERCP.

Eligibility criteria

Qualifiers

Age≥18years

The ASA classification ranges from I to III

Patients have signed the informed consent form

Patients scheduled to undergo sedated ERCP examination procedure

Disqualifiers

Severe cardiac dysfunction (<4 METs);

Diagnosed chronic obstructive pulmonary disease (COPD) or other acute/chronic pulmonary diseases requiring long-term/intermittent oxygen therapy;

Upper respiratory tract infections including oral, nasal or pharyngeal infections;

Fever (core temperature >37.5°C);

Trial design

Treatments tested in this trial

  • The Supraglottic Oxygenation Via Oral Transtracheal Catheter Group
  • The Regular Nasal Cannula

Treatment groups

410 Participants
are divided into 2 treatment groups

Sponsors and collaborators